My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: Usually no — compounded GLP‑1s are not the best first option. They carry safety, quality, legal, and efficacy uncertainties. Try appeals, manufacturer assistance, or covered FDA‑approved alternatives first. I can help you with next steps.

Why compounded GLP‑1s are risky

• Not FDA‑approved: Potency, purity, sterility and bioequivalence aren’t guaranteed.
• Quality/sterility concerns: Injections need sterile, accredited compounding (USP <797>); errors can cause serious infections.
• Legal/regulatory issues: Pharmacies shouldn’t compound copies of an FDA‑approved product when an approved product exists; insurance and doctors may reject them.
• Unknown reimbursement: Many insurers won’t pay for compounded formulations.

Safer alternatives to try (with specific names)

• Appeal the denial: Ask your prescriber for a prior‑authorization appeal or peer‑to‑peer review. Document medical necessity (BMI, comorbidities) and cite guideline support for GLP‑1 use.
• Manufacturer support/coupons:
  • Novo Nordisk (Wegovy/Saxenda): offers savings programs and patient support — useful if you’re commercially insured.
  • Eli Lilly (Zepbound, Mounjaro): contact Lilly for savings programs or patient assistance if tirzepatide is an option.
• Try an alternative FDA‑approved drug that might be covered:
  • Saxenda (liraglutide) — FDA‑approved for weight loss; insurance sometimes covers it differently than Wegovy.
  • Zepbound (tirzepatide for weight) or Mounjaro (tirzepatide for diabetes) — newer and highly effective; coverage varies.
  • Ozempic/Rybelsus (semaglutide for diabetes) — sometimes covered for diabetes and used off‑label under close provider guidance.
• Discount tools and clinics:
  • GoodRx / SingleCare: coupons that can reduce out‑of‑pocket cost at retail pharmacies.
  • Telehealth weight‑management clinics (e.g., Ro, Hims & Hers, One Medical, local weight‑loss clinics): some have negotiated prices or assistance programs — confirm they use FDA products.

What I recommend you do now

1. Ask your provider to start an appeal/prior‑authorization with clinical documentation and, if needed, request a peer‑to‑peer with the insurer.
2. Contact the drug manufacturer’s patient support program (Novo Nordisk for Wegovy; Lilly for tirzepatide) about savings cards or patient assistance.
3. Ask your clinician about alternative FDA‑approved GLP‑1 or GIP/GLP‑1 options (Saxenda, Zepbound/Mounjaro, Ozempic) that your insurer may cover.
4. Only consider compounded products if you exhaust all above options and:
   • You confirm the compounding pharmacy is USP <797> accredited and state‑licensed,
   • You understand and accept the extra safety and legal risks,
   • Your prescriber documents why no FDA‑approved product is acceptable.

If you’d like, tell me:

• Is your insurance commercial, Medicare, or Medicaid?
• Do you have a copy of the denial reason?

I can help draft an appeal letter or look up manufacturer/patient‑assistance contact info and possible covered alternatives for your plan.